Cellix Bio

Award Winner

Amazing Prospects

Adding our novel chemistries to improve existing compounds and create New Molecular Entities (NMEs) eligible for strong intellectual property protectionOur biopharmaceutical candidates may be eligible for regulatory pathways associated with relatively short approval times and low development costs

Flexible Works

Completely incubate worldwide users before imperatives and delivering science with a purpose for better clinical outcomes

Synergix

Developing new therapies for the treatment of ophthalmic, neurological, inflammatory, metabolic, oncology and other diseases

What We Do

Cellix Bio is an innovative biopharmaceutical company dedicated to the development of proprietary molecular therapeutics that enhance one or more of the attributes of approved drugs, such as efficacy, therapeutic index, bioavailability and safety.

Our business model aims to create value with a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our mission is to participate in the promise of the biotech industry with a profitable, diversified business that is lower in risk than a typical biotech company. We aspire to contribute positively to the healthcare system, and improve the lives of patients around the world. Cellix Bio therapeutic portfolio is focused on diverse therapeutic areas including neurology, dermatology, gastrointestinal, inflammation, metabolic & life style, oncology, ophthalmology and infectious diseases.

Cellix Bio intends to develop targeted therapies

based on proprietary prodrugs with improved properties relative to approved drugs; we will address unmet medical needs in the U.S., India, established markets and emerging markets (CIS, Asia, Africa, Latin America etc.)

Metabolic Diseases

Pain and Inflammation

Dermatology

Superior in transformation of ideas

Building a biopharmaceutical company with selective new technologies, ideas, medicines, and insights leading to superior transformation of ideas; our core competence is to develop and commercialize therapeutic drug products with less development risk and unique benefits for patients within our therapeutic areas of focus

Strong scientific platform Synergix

Using our proprietary technologies and our “Synergix” scientific platform, we are developing new medicines that modulate more than one target in the disease pathway, which potentially improves efficacy and minimizes risk in the discovery and development process.

Team Work

Our team has unique scientific and entrepreneurial experience in the life science industry, including R & D management, formulation development, and business development in renowned biopharmaceutical companies.

We aim to develop best-in-class therapies for the treatment of neurological, inflammatory, metabolic, and other diseases

Global Patents

Issued U.S. Patents

Pending U.S. Patents

Project Management

Cellix Bio bags 2017 Fastest Growing Indian Company Excellence Award. The award will be presented during the National Seminar & Awards Ceremony on “Individual Achievements & National Development” at New Delhi.

National Seminar
New Delhi

Cellix Bio’s CLX-117 pipeline lead candidate qualifies for UConn SPARK Technology Commercialization Fund Program 2016 with the investigative supervision of Dr. Rajesh V Lalla. The award aims to help investigators from UConn-Storrs and UConn Health (UCH) move ideas into the earliest stages of commercialization and development.

Dr. Jeff Seemann
UConn SPARK Technology

Cellix Bio and New Jersey Medical School, Rutgers; collaboration is focused to screen novel anti-fungal compounds developed and patented by Cellix Bio. These novel therapies are focused to address the drug resistance in pathogenic fungal infections.